Fortrea Holdings (FTRE) Change in Accured Expenses (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Change in Accured Expenses came in at $25.1 million in Q2 2026, down 1.18% YoY from $25.4 million in Q2 2025, and up 157.83% on a QoQ basis from -$43.4 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Change in Accured Expenses data on file, last reported at $25.1 million in Q2 2026.
- Quarterly Change in Accured Expenses fell 1.18% year-over-year to $25.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$10.1 million (down 138.4% YoY) and the FY2025 annual result came in at $6.5 million, up 30.0% from the prior year.
- Change in Accured Expenses advanced to $25.1 million in Q2 2026, from -$43.4 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $80.3 million in Q2 2023 to a low of -$65.1 million in Q1 2023.
- A 5-year average of -$1.7 million and a median of -$17.6 million in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 96.26% — and 2025, when it surged 746.67%.
- Tracing FTRE's Change in Accured Expenses over 5 years: stood at -$22.7 million in 2022, then soared by 253.3% to $34.8 million in 2023, then surged by 39.94% to $48.7 million in 2024, then plunged by 53.39% to $22.7 million in 2025, then advanced by 10.57% to $25.1 million in 2026.
- The last three Change in Accured Expenses figures came in at $25.1 million (Q2 2026), -$43.4 million (Q1 2026), and $22.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Fortrea Holdings | 1.73 Bn | 1.56 Bn | 139.20 Mn | 25.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.10 Mn |
| Mar 31, 2026 | -43.40 Mn |
| Dec 31, 2025 | 22.70 Mn |
| Sep 30, 2025 | -14.50 Mn |
| Jun 30, 2025 | 25.40 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Dec 31, 2024 | 48.70 Mn |
| Sep 30, 2024 | -20.70 Mn |
| Jun 30, 2024 | 3.00 Mn |
| Mar 31, 2024 | -26.00 Mn |
| Dec 31, 2023 | 34.80 Mn |
| Sep 30, 2023 | -23.80 Mn |
| Jun 30, 2023 | 80.30 Mn |
| Mar 31, 2023 | -65.10 Mn |
| Dec 31, 2022 | -22.70 Mn |
| Sep 30, 2022 | -24.00 Mn |